Showing 8041-8050 of 8647 results for "".
- Glauconix Biosciences Promotes Kimberly Southern to Chief Executive Officerhttps://modernod.com/news/glauconix-biosciences-promotes-kimberly-southern-to-chief-executive-officer/2477262/Glauconix Biosciences announced that its board of directors has appointed Kim Southern as Chief Executive Officer and a member of the Board of Directors effective immediately. Ms. Southern previously held the position of Chief Operating Officer. Since joining the company in May, Ms. Southe
- The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial of Tepezza for Thyroid Eye Diseasehttps://modernod.com/news/the-new-england-journal-of-medicine-publishes-comprehensive-data-from-phase-3-clinical-trial-of-tepezza-for-thyroid-eye-disease/2477252/Horizon Therapeutics announced that The New England Journal of Medicine has published
- Mojo Vision Developing Smart Contact Lenshttps://modernod.com/news/mojo-vision-developing-smart-contact-lens/2477237/Mojo Vision announced it is building what it calls the “world’s first true smart contact lens,” called the Mojo Lens. Mojo Lens is a contact lens with a built-in display that gives people useful and timely information without forcing them to look down at a screen or losing focus on th
- Kala Pharmaceuticals Completes of Enrollment of STRIDE 3 Trial for Eysuvis for Dry Eye Diseasehttps://modernod.com/news/kala-pharmaceuticals-announces-completion-of-enrollment-of-stride-3-trial-for-eysuvis-for-dry-eye-disease/2477232/Kala Pharmaceuticals announced that it has completed enrollment in its STRIDE 3 (STRIDE – Short Term Relief In Dry Eye) phase 3 clinical trial for KPI-121 0.25%, its product candidate for the short-term treatment of dry eye disease. If approved, Kala plans to commercialize KPI-121 0.25% under the
- Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharmas-oc-01-nasal-spray-meets-primary-endpoint-in-phase-2-mystic-trial-in-subjects-with-dry-eye-disease/2477225/Oyster Point Pharma announced positive topline results from its phase 2 MYSTIC study in dry eye disease. Results showed a statistically significant improvement in Schirmer’s score from baseline at Day 84 in both doses as compared to control.
- Watchdog: NHS Delays Responsible for Glaucoma Patients Going Blindhttps://modernod.com/news/watchdog-nhs-delays-responsible-for-glaucoma-patients-going-blind/2477221/Long delays to treatment on the NHS have been responsible for glaucoma patients losing their sight, a safety watchdog in the UK has warned, according to a report in Independent. The
- Ideaya Biosciences and Boston Children’s Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndromehttps://modernod.com/news/ideaya-biosciences-and-boston-childrens-hospital-collaborate-on-preclinical-evaluation-of-ide196-for-sturge-weber-syndrome/2477220/Ideaya Biosciences announced that the company has entered into a Sponsored Research Agreement with Boston Children’s Hospital for preclinical evaluation of the role of protein kinase C (PKC) in Sturge Weber syndrome (SWS), a rare neurocutaneous disorder characterized by capillary malformati
- US Cancer Death Rates Are Dropping at the Fastest Pace on Recordhttps://modernod.com/news/us-cancer-death-rates-are-dropping-at-the-fastest-pace-on-record/2477215/The cancer death rate in the U.S. fell by the most on record as advances in treatments for lung tumors like video-assisted surgery helped prolong the lives of patients, according to a Bloomberg
- New Chair, Members Named to Eversight Board of Directorshttps://modernod.com/news/new-chair-members-named-to-eversight-board-of-directors/2477217/Eversight announced that two new members and a new chair have been named to its Board of Directors, effective Jan. 1, 2020. Joining the Eversight Board of Directors are Carolyn Welsh, Vice President & Chief Clinical Officer, NJ Sharing Network; and Mahmoud N. Ghazzi, MD, PhD, MPH, an e
- Tarsus Pharmaceuticals Raises $60 Million for Demodex Blepharitis Drug Trialhttps://modernod.com/news/tarsus-pharmaceuticals-raises-60-million-for-demodex-blepharitis-drug-trial/2477213/Tarsus Pharmaceuticals announced the completion of $60 million in Series B financing. Tarsus will use the funds to initiate a phase 2b/3 trial in the United States of their lead product TP-03 for Demodex blepharitis and fuel phase 1 and 2 development of other clinical programs. An estimate